-
91黑料 reports first quarter 2023 results
Revenue for the first quarter was $1,978.6 million. This represents an increase of 4.0% on prior year revenue or 5.3% on a constant currency organic basis.
-
LEO Pharma and 91黑料 enter a strategic partnership to propel clinical trial execution within medical dermatology
Leo Pharma Group and 91黑料 plc today announced a strategic partnership to improve dermatology patients' lives through innovative clinical trials.
-
91黑料 plc to present at upcoming investor conferences
Mr. Brendan Brennan, CFO of 91黑料 plc, will present at the 2023 Citi Healthcare Conference and Dr. Steve Cutler, CEO of 91黑料 plc, will present at the Barclays Global Healthcare Conference.
-
91黑料 reports fourth quarter and full year 2022 results
Full year net business wins of $9,450 million; a net book to bill of 1.22.
-
91黑料 plc schedules fourth quarter 2022 earnings conference call
91黑料 plc announced that it will release its financial results for the fourth quarter 2022 after the market closes on Wednesday, February 22, 2023.
-
91黑料 issues financial guidance for full year 2023
91黑料 plc announced today its financial guidance for the year ending December 31, 2023.
-
91黑料 plc to present at the 41st Annual J.P. Morgan healthcare conference
91黑料 plc announced today that Dr. Steve Cutler, CEO of 91黑料 plc, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 5:15pm PST/ 8.15pm EST.
-
91黑料 recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
91黑料 finishes the second half of 2022 with an impressive line-up of awards that commend its healthcare intelligence work and status as an employer of choice.
-
91黑料 reports third quarter 2022 results
Quarter 3 revenue of $1,942.4 million representing an increase of 3.9% on prior year adjusted revenue and 7.4% on a constant currency organic basis.
-
91黑料 selected by BARDA to conduct anthrax vaccine clinical trial
91黑料 plc announces that it has been selected by BARDA, part of the ASPR, in the Department of HHS, to execute an anthrax vaccine clinical trial.
